GlassScriptPhysician profile
Howard A Benn
NPI 1841364965
$21,424.85
in general payments reported to CMS, 2019-2025
67 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,712 · 2020: $1,343 · 2021: $5,997 · 2022: $4,323 · 2023: $2,369 · 2024: $2,405 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,278 · Education: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,277.81 |
| Education | $770.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,498.64 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Global Blood Therapeutics, INC. | $3,022.34 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,637.94 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Puma Biotechnology, INC. | $1,149.01 | 2019-2025 | |
| Amgen INC. | $1,002.86 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Merck Sharp & Dohme LLC | $974.52 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $854.80 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $853.66 | 2019-2025 | |
| Celgene Corporation | $717.07 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $650.55 | 2019-2025 | |
| Daiichi Sankyo INC. | $564.68 | 2019-2025 | Enhertu, Injectafer |
| Genentech USA, INC. | $454.42 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Pfizer INC. | $451.40 | 2019-2025 | |
| Astellas Pharma US INC | $447.95 | 2020-2025 | Xtandi, Vyloy, Xospata |
| Seagen INC. | $435.02 | 2019-2023 | Padcev, Tukysa, Adcetris |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $390.07 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $386.55 | 2019-2025 | Iclusig, Alunbrig, Ninlaro |
| Gilead Sciences, INC. | $282.66 | 2019-2025 | Trodelvy |
| Incyte Corporation | $263.66 | 2019-2025 | Jakafi |
| Lilly USA, LLC | $245.83 | 2019-2022 | |
| Medtronic, INC. | $235.06 | 2022-2024 | Minimed 780g |
| Exelixis INC. | $210.58 | 2021-2025 | Cabometyx |
| Sirtex Medical INC | $204.04 | 2019-2023 | Sir-Spheres Microspheres |
| Genzyme Corporation | $175.64 | 2021-2025 | |
| Kite Pharma, INC. | $149.70 | 2020-2025 | Yescarta |
| Acrotech Biopharma INC. | $138.44 | 2021-2025 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.87 | 2019-2023 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $127.71 | 2022-2024 | |
| Emmaus Medical, INC. | $124.19 | 2022-2024 | Endari |
| Adaptive Biotechnologies Corporation | $111.58 | 2022-2025 | Clonoseq |
| Emd Serono, INC. | $104.70 | 2022-2025 | Tepmetko |
| Taiho Oncology, INC. | $96.98 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $96.63 | 2019-2023 | Libtayo |
| Myovant Sciences INC. | $87.70 | 2021-2022 | |
| Tempus Ai, INC | $83.64 | 2024-2025 | Xt Cdx |
| Abbvie INC. | $73.75 | 2021-2025 | |
| Mirati Therapeutics, INC. | $65.96 | 2023 | Krazati |
| Stemline Therapeutics INC. | $62.81 | 2025 | Orserdu |
| Janssen Scientific Affairs, LLC | $62.75 | 2022-2023 | Erleada |
| Pharmacosmos Therapeutics INC. | $60.87 | 2022-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $57.52 | 2019-2023 | Tavalisse, Rezlidhia |
| Ipsen Biopharmaceuticals, INC | $52.50 | 2021 | |
| Blueprint Medicines Corporation | $50.97 | 2023-2025 | Ayvakit |
| Servier Pharmaceuticals LLC | $47.27 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $46.60 | 2020 | |
| Macrogenics, INC. | $44.08 | 2022-2023 | |
| Glaxosmithkline, LLC. | $38.65 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $36.82 | 2020-2024 | Provenge |
| Sumitomo Pharma America, INC. | $35.83 | 2023-2024 | Orgovyx |
| Beone Medicines USA, INC. | $33.95 | 2025 | Brukinsa |
| Array Biopharma INC | $31.80 | 2021-2024 | Mektovi, Lorbrena, Braftovi |
| Jazz Pharmaceuticals INC. | $29.87 | 2024-2025 | |
| Epizyme, INC. | $25.04 | 2020-2021 | |
| G1 Therapeutics, INC. | $24.34 | 2023 | Cosela |
| Secura Bio, INC. | $17.77 | 2021 | |
| Sobi, INC | $17.71 | 2022 | |
| Horizon Therapeutics Plc | $16.51 | 2023 | Krystexxa |
| Geron Corporation | $16.25 | 2025 | Rytelo |
| Beigene USA, INC. | $15.89 | 2023 | Brukinsa |
| Pharmaessentia USA Corporation | $15.50 | 2023 | Besremi |
| Cti Biopharma Corp. | $14.99 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $13.31 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.31 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.92 | 2022 | |
| Novocure INC. | $12.85 | 2021 | |
| Karyopharm Therapeutics INC. | $12.37 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Benn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.